Trial reportWorld journal of gastroenterology2008
Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis.
Trial report in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Prevalence and risk factors of erectile dysfunction in patients with liver cirrhosis: a systematic review and meta-analysis.Hepatology international · 2023Pooled it
- Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: a randomized double blind placebo controlled trial.Hepatology international · 2023Trial
- Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy.World journal of gastroenterology · 2023Review
- Sexual dysfunctions and their treatment in liver diseases.World journal of hepatology · 2022Review
- Chronic liver diseases and erectile dysfunction.Frontiers in public health · 2022Review
- Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications.International journal of molecular sciences · 2021Review
- Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.International journal of molecular sciences · 2020Review
- Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats.Pharmaceutics · 2020Article
- Treatment Barriers in Portopulmonary Hypertension.Hepatology (Baltimore, Md.) · 2019Review
- Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.World journal of gastroenterology · 2018Article
- Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension.Liver international : official journal of the International Association for the Study of the Liver · 2018Article
- Novel treatment options for portal hypertension.Gastroenterology report · 2017Article
- [Urological aspects in patients with liver cirrhosis].Der Urologe. Ausg. A · 2016Review
- Smooth muscle contractile diversity in the control of regional circulations.American journal of physiology. Heart and circulatory physiology · 2014Review
- Haemodynamic and renal effects of tadalafil in patients with cirrhosis.World journal of gastroenterology · 2010Article
- Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2010Article
- Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver.BMC gastroenterology · 2009Article
- Does Treatment of Erectile Dysfunction With PDE 5 Inhibitor Tadalafil Improve Quality of Life in Male Patients With Compensated Chronic Liver Disease? A Prospective Pilot Study.Journal of clinical and experimental hepatologyArticle
- Tadalafil, a Phosphodiesterase-5 Inhibitor, Improves Erectile Dysfunction in Patients With Liver Cirrhosis.Journal of clinical and experimental hepatologyArticle
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate if sildenafil increases splanchnic blood flow and changes the hepatic venous pressure gradient (HVPG) in patients with cirrhosis. Phosphodiesterase type-5 inhibitors are valuable in the treatment of erectile dysfunction and pulmonary hypertension in patients with end-stage liver disease. However, the effect of phosphodiesterase type-5 inhibitors on splanchnic blood flow and portal hypertension remains essentially unknown.
methodsTen patients with biopsy proven cirrhosis (five females/five males, mean age 54 +/- 8 years) and an HVPG above 12 mmHg were studied after informed consent. Measurement of splanchnic blood flow and the HVPG during liver vein catheterization were done before and 80 min after oral administration of 50 mg sildenafil. Blood flow was estimated by use of indocyanine green clearance technique and Fick's principle, with correction for non-steady state.
resultsThe plasma concentration of sildenafil was 222 +/- 136 ng/mL 80 min after administration. Mean arterial blood pressure decreased from 77 +/- 7 mmHg to 66 +/- 12 mmHg, P = 0.003, while the splanchnic blood flow and oxygen consumption remained unchanged at 1.14 +/- 0.71 L/min and 2.3 +/- 0.6 mmol/min, respectively. Also the HVPG remained unchanged (18 +/- 2 mmHg vs 16 +/- 2 mmHg) with individual changes ranging from -8 mmHg to +2 mmHg. In seven patients, HVPG decreased and in three it increased.
conclusionIn spite of arterial blood pressure decreases 80 min after administration of the phosphodiesterase type-5 inhibitor sildenafil, the present study could not demonstrate any clinical relevant influence on splanichnic blood flow, oxygen consumption or the HVPG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.